SAN DIEGO--(BUSINESS WIRE)--Imagenetix, Inc. (OTCBB: IAGX) today announced that its proprietary anti-inflammatory compound, 1-tetradecanol complex (1-TDC), intended for use in the treatment of periodontal disease and other widespread inflammatory conditions, has completed pre-IND assessment by the FDA Dental and Dermatology Division and received positive comments.
